Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies

The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) erlotinib has been approved for years as a first-line therapy for patients harboring EGFR-sensitizing mutations. With the promising implementation of immunotherapeutic strategies for the treatment of lung cancer, there is a gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dominguez, Charli, Tsang, Kwong-Yok, Palena, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059888/
https://www.ncbi.nlm.nih.gov/pubmed/27685624
http://dx.doi.org/10.1038/cddis.2016.297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059888/
https://www.ncbi.nlm.nih.gov/pubmed/27685624
http://dx.doi.org/10.1038/cddis.2016.297

Ejemplares similares